Advertisement
Singapore markets close in 1 hour 22 minutes

  • Straits Times Index

    3,284.83
    -8.30 (-0.25%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,269.60
    +68.33 (+0.40%)
     

  • FTSE 100

    8,076.06
    +35.68 (+0.44%)
     

  • Bitcoin USD

    64,180.18
    -2,629.05 (-3.94%)
     

  • CMC Crypto 200

    1,390.67
    +8.10 (+0.59%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,334.20
    -4.20 (-0.18%)
     

  • Crude Oil

    82.99
    +0.18 (+0.22%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.08
    -1.40 (-0.09%)
     

  • Jakarta Composite Index

    7,149.18
    -25.35 (-0.35%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

US regulators OK updated version of decades-old antibiotic

U.S. regulators approve Paratek's new antibiotic designed to overcome the worsening problem of bacteria resisting treatment

Linda a. Johnson, AP Medical Writer

TRENTON, N.J. (AP) -- U.S. regulators have approved a modernized version of a decades-old antibiotic used to treat a number of infections.

Paratek Pharmaceuticals' Nuzyra (noo-ZAHY'-ruh) was designed to overcome the problem of resistance to tetracycline, an antibiotic widely used until recent years.

The company said late Tuesday that the Food and Drug Administration approved Nuzyra for treating bacterial pneumonia and severe skin infections.

Paratek plans to launch the antibiotic early next year, initially for use in hospitals. It hasn't disclosed the price.

Boston-based Paratek estimates its drug could eventually treat nearly 900,000 hospitalized U.S. patients annually.